Anthrax vaccination induced anti-lethal factor IgG: Fine specificity and neutralizing capacity

Vaccine

Volumn 29, Issue 20, 2011, Pages 3670-3678

  Crowe, Sherry R ^a   Garman, Lori ^a,b   Engler, Renata J M ^c   Farris, A Darise ^a,b   Ballard, Jimmy D ^b   Harley, John B ^b,d   James, Judith A ^a,b  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Anthrax; Anthrax vaccine adsorbed; Bacillus anthracis; Correlate of protection; Lethal factor; Protective antigen

Indexed keywords

ANTHRAX VACCINE; EPITOPE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY;

ADULT; AFRICAN AMERICAN; ANTHRAX; ANTIBODY PRODUCTION; ARTICLE; EUROPEAN AMERICAN; FEMALE; HUMAN; IMMUNOGENETICS; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RACE DIFFERENCE; VACCINATION;

ADULT; AFRICAN AMERICANS; ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; ENDPOINT DETERMINATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MICE; NEUTRALIZATION TESTS;

EID: 79955113963     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.011     Document Type: Article

References (45)

1. Mourez M. Anthrax toxins. Rev Physiol Biochem Pharmacol 2004, 152:135-164.
2. Brossier F., Weber-Levy M., Mock M., Sirard J.C. Role of toxin functional domains in anthrax pathogenesis. Infect Immun 2000, 68:1781-1786.
3. Scobie H.M., Young J.A. Interactions between anthrax toxin receptors and protective antigen. Curr Opin Microbiol 2005, 8:106-112.
4. Gordon V.M., Klimpel K.R., Arora N., Henderson M.A., Leppla S.H. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 1995, 63:82-87.
5. Lacy D.B., Wigelsworth D.J., Melnyk R.A., Harrison S.C., Collier R.J. Structure of heptameric protective antigen bound to an anthrax toxin receptor: A role for receptor in ph-dependent pore formation. Proc Natl Acad Sci USA 2004, 101:13147-13151.
6. Firoved A.M., Miller G.F., Moayeri M., Kakkar R., Shen Y., Wiggins J.F., et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol 2005, 167:1309-1320.
7. Kumar P., Ahuja N., Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic amp toxicity in target cells. Infect Immun 2002, 70:4997-5007.
8. Starnbach M.N., Collier R.J. Anthrax delivers a lethal blow to host immunity. Nat Med 2003, 9:996-997.
9. Paccani S.R., Tonello F., Ghittoni R., Natale M., Muraro L., D'Elios M.M., et al. Anthrax toxins suppress t lymphocyte activation by disrupting antigen receptor signaling. J Exp Med 2005, 201:325-331.
10. Pannifer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Bienkowska J., et al. Crystal structure of the anthrax lethal factor. Nature 2001, 414:229-233.
11. Popov S.G., Villasmil R., Bernardi J., Grene E., Cardwell J., Popova T., et al. Effect of bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett 2002, 527:211-215.
12. Liang X., Young J.J., Boone S.A., Waugh D.S., Duesbery N.S. Involvement of domain ii in toxicity of anthrax lethal factor. J Biol Chem 2004, 279:52473-52478.
13. Miyoshi S., Shinoda S. Microbial metalloproteases and pathogenesis. Microbes Infect 2000, 2:91-98.
14. Little S.F., Leppla S.H., Friedlander A.M. Production and characterization of monoclonal antibodies against the lethal factor component of bacillus anthracis lethal toxin. Infect Immun 1990, 58:1606-1613.
15. Little S.F., Ivins B.E., Fellows P.F., Friedlander A.M. Passive protection by polyclonal antibodies against bacillus anthracis infection in guinea pigs. Infect Immun 1997, 65:5171-5175.
16. Little S.F., Leppla S.H., Cora E. Production and characterization of monoclonal antibodies to the protective antigen component of bacillus anthracis toxin. Infect Immun 1988, 56:1807-1813.
17. Use of anthrax vaccine in the United States: Recommendations of the advisory committee on immunization practices. J Toxicol Clin Toxicol 2001, 39:85-100.
18. Leppla S.H., Robbins J.B., Schneerson R., Shiloach J. Development of an improved vaccine for anthrax. J Clin Invest 2002, 110:141-144.
19. Pezard C., Weber M., Sirard J.C., Berche P., Mock M. Protective immunity induced by bacillus anthracis toxin-deficient strains. Infect Immun 1995, 63:1369-1372.
20. Albrecht M.T., Li H., Williamson E.D., Lebutt C.S., Flick-Smith H.C., Quinn C.P., et al. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against bacillus anthracis infection and enhance endogenous immunity to anthrax. Infect Immun 2007, 75:5425-5433.
21. Brossier F., Levy M., Landier A., Lafaye P., Mock M. Functional analysis of bacillus anthracis protective antigen by using neutralizing monoclonal antibodies. Infect Immun 2004, 72:6313-6317.
22. Chen Z., Moayeri M., Crown D., Emerson S., Gorshkova I., Schuck P., et al. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor: evidence for possible synergy with anti-pa antibody. Infect Immun 2009.
23. Nguyen M.L., Crowe S.R., Kurella S., Teryzan S., Cao B., Ballard J.D., et al. Sequential b-cell epitopes of bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies. Infect Immun 2009, 77:162-169.
24. Staats H.F., Alam S.M., Scearce R.M., Kirwan S.M., Zhang J.X., Gwinn W.M., et al. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect Immun 2007, 75:5443-5452.
25. Zhao P., Liang X., Kalbfleisch J., Koo H.M., Cao B. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum Antibodies 2003, 12:129-135.
26. Quinn C.P., Semenova V.A., Elie C.M., Romero-Steiner S., Greene C., Li H., et al. Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin g antibodies to anthrax toxin protective antigen. Emerg Infect Dis 2002, 8:1103-1110.
27. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., et al. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect Immun 2004, 72:3276-3283.
28. Crowe S.R., Ash L.L., Engler R.J., Ballard J.D., Harley J.B., Farris A.D., et al. Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis 2010, 202:251-260.
29. McClain M.T., Poole B.D., Bruner B.F., Kaufman K.M., Harley J.B., James J.A. An altered immune response to epstein-barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006, 54:360-368.
30. James J.A., Harley J.B. Human lupus anti-spliceosome a protein autoantibodies bind contiguous surface structures and segregate into two sequential epitope binding patterns. J Immunol 1996, 156:4018-4026.
31. Arbuckle M.R., Gross T., Scofield R.H., Hinshaw L.B., Chang A.C., Taylor F.B., et al. Lupus humoral autoimmunity induced in a primate model by short peptide immunization. J Investig Med 1998, 46:58-65.
32. Allen J.S., Skowera A., Rubin G.J., Wessely S., Peakman M. Long-lasting t cell responses to biological warfare vaccines in human vaccinees. Clin Infect Dis 2006, 43:1-7.
33. McClain M.T., Lutz C.S., Kaufman K.M., Faig O.Z., Gross T.F., James J.A. Structural availability influences the capacity of autoantigenic epitopes to induce a widespread lupus-like autoimmune response. Proc Natl Acad Sci USA 2004, 101:3551-3556.
34. Baillie L., Townend T., Walker N., Eriksson U., Williamson D. Characterization of the human immune response to the uk anthrax vaccine. FEMS Immunol Med Microbiol 2004, 42:267-270.
35. Belova E.V., Kolesnikov A.V., Zakharova M.Y., Dubiley S.A., Dyatlov I.A., Shemyakin I.G. Special features of immune response to the lethal toxin of bacillus anthracis. Russ J Bioorg Chem+ 2008, 34:571-577.
36. Hepburn M.J., Hugh Dyson E., Simpson A.J., Brenneman K.E., Bailey N., Wilkinson L., et al. Immune response to two different dosing schedules of the anthrax vaccine precipitated (avp) vaccine. Vaccine 2007, 25:6089-6097.
37. Marano N., Plikaytis B.D., Martin S.W., Rose C., Semenova V.A., Martin S.K., et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008, 300:1532-1543.
38. Gardner E.M., Gonzalez E.W., Nogusa S., Murasko D.M. Age-related changes in the immune response to influenza vaccination in a racially diverse, healthy elderly population. Vaccine 2006, 24:1609-1614.
39. Gelder C.M., Lambkin R., Hart K.W., Fleming D., Williams O.M., Bunce M., et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002, 185:114-117.
40. Ovsyannikova I.G., Jacobson R.M., Poland G.A. Variation in vaccine response in normal populations. Pharmacogenomics 2004, 5:417-427.
41. Dhiman N., Ovsyannikova I.G., Vierkant R.A., Ryan J.E., Shane Pankratz V., Jacobson R.M., et al. Associations between snps in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 2008, 26:1731-1736.
42. Dhiman N., Poland G.A., Cunningham J.M., Jacobson R.M., Ovsyannikova I.G., Vierkant R.A., et al. Variations in measles vaccine-specific humoral immunity by polymorphisms in slam and cd46 measles virus receptors. J Allergy Clin Immunol 2007, 120:666-672.
43. Hohler T., Reuss E., Evers N., Dietrich E., Rittner C., Freitag C.M., et al. Differential genetic determination of immune responsiveness to hepatitis b surface antigen and to hepatitis a virus: a vaccination study in twins. Lancet 2002, 360:991-995.
44. Yucesoy B., Sleijffers A., Kashon M., Garssen J., de Gruijl F.R., Boland G.J., et al. Il-1beta gene polymorphisms influence hepatitis b vaccination. Vaccine 2002, 20:3193-3196.
45. Tang Y.W., Li H., Wu H., Shyr Y., Edwards K.M. Host single-nucleotide polymorphisms and altered responses to inactivated influenza vaccine. J Infect Dis 2007, 196:1021-1025.